Medtronic, Inc. (Jobs) Files PMA Application for FDA Approval of Talent(TM) Abdominal Stent Graft System

Published: Dec 03, 2007

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT), today announced that it has filed the final module of its Pre-Market Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the Talent™ Abdominal Stent Graft System. The Talent Abdominal Stent Graft is a minimally-invasive device that treats dangerous bulges in the aorta, the body’s largest artery that can rupture without warning.

Back to news